Liquidia Technlogies Receives Significant Equity Investment to Bolster Development of Next Generation Vaccines

Bill & Melinda Gates Foundation invests in the future of global disease prevention

RESEARCH TRIANGLE PARK, N.C. -- Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment (PRI) in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).

“We are delighted the Gates Foundation has decided to join an outstanding group of investors that share our confidence in the potential of PRINT® technology to improve vaccine delivery and effectiveness,” said Neal Fowler, Chief Executive Officer at Liquidia. “As the field of vaccines continues to grow, success will be defined by our ability to produce and deliver highly efficacious therapies in quantities and costs that will support the global demand.”

Read the full press release
(PDF, 80KB, 2 pages) http://www.liquidia.com/press/Liquidia_Gates_PR.pdf

###
Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.